Corporate venture funds fill drop off in biotech investment

11/15/2011 | Bloomberg Businessweek

Corporate venture funds are increasingly filling biotech firms' funding needs, according to analysts. Corporate venture funds were tied to 25% of early-stage U.S. biotech financing deals during the first half of 2011, compared with 15% in all of 2010, according to PricewaterhouseCoopers and the National Venture Capital Association. Amgen Ventures said it has funded 26 companies since it started in 2004.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA